Prince of Songkla University - Hat Yai Campus: Prince of Songkla University
Hat Yai, Changwat Songkhla, 90110, Thailand
Location status: Recruiting
Location contact
Thareerat Ananchaisarp
CONTACT
NCT Number: NCT06265870
There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Hat Yai, Changwat Songkhla, 90110, Thailand
Location status: Recruiting
Thareerat Ananchaisarp
CONTACT
Eosinophilia is defined as an absolute eosinophil count exceeding 500 cells per microliter, calculated by multiplying the white blood cell count by the percentage of eosinophils.
Cause of eosinophilia vary from mild to life-threatening disease. Prevalence of each cause of eosinophilia vary on study population, the most common etiology in developing country is parasite infection.
Stool microscopy can be conducted using various methods. The Kato-Katz technique, recommended by the WHO, exhibits a sensitivity of only 52.4 percent (95%CI = 47.6 - 57.1 percent). More sensitive methods for parasite detection in stool, such as stool culture or PCR, are not readily available and can be costly. In the intervention group of this study, the investigators employed three different parasite detection methods (stool microscopy, stool culture, and PCR) to enhance sensitivity in detecting parasites.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1.2 Physical examination revealed a body temperature equal to or greater than 37.8 degrees Celsius, lymphadenopathy or hepatosplenomegaly.
1.3 CBC revealed blast cell
Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
Time frame: From receive anthelminthic treatment to the end of treatment at 4 weeks
Recovery from eosinophilia was defined as an absolute eosinophil count of less than 500 cells per microliter, as measured from the complete blood count (CBC) four weeks after receiving anthelminthic treatment.
Time frame: From receive anthelminthic treatment to the end of treatment at 4 weeks
Comparing the change in AEC from baseline between the "specific treatment group" and the "empirical treatment group" using either a paired t-test or the Wilcoxon signed-rank test.
Contact information is provided by the study sponsor or research team.
Thareerat Ananchaisarp
CONTACT
Wisarut Srisintorn
CONTACT
Prince of Songkla University
Other
Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient
Acronym: Eosinophilia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00091871
Eosinophilia, Hematologic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00001406
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04018118
Eosinophilia, Hematologic Diseases
Lille, France
View Trial DetailsNCT03801434
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells
Palo Alto, California, United States
View Trial Details